Emerald Health Therapeutics to Lead International Affairs Council on CBD and Hemp’s Dialog with FDA on CBD Product Policy ...
May 24 2019 - 07:00AM
Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX:
EMHTF) has been appointed by the American Trade Association for
Cannabis and Hemp (ATACH) to lead its International Affairs Council
on CBD and Hemp in ATACH’s engagement with the US Food & Drug
Administration (FDA) regarding policy pertaining to CBD-containing
products and associated cross-border trade. The FDA is slated to
begin public consultation on May 31 to discuss potential pathways
for CBD products to come to market in the US.
“Emerald Health Therapeutics is one of Canada’s
original Licenced Producers and has expertise on CBD extraction and
associated regulatory development,” said Michael Bronstein,
President of ATACH. “We look forward to leveraging Emerald’s
knowledge and experience as we participate in the FDA process on
how to best navigate and implement a potentially-new regime for
products containing cannabinoids in the United States.”
“We are pleased to be asked to lead ATACH’s
International Affairs Council on CBD and Hemp,” said Dr. Avtar
Dhillon, President and Executive Chairman of Emerald. “We believe
there is significant therapeutic and economic potential for
CBD-related products generally and in the US, and we are eager to
play a positive role in this policy formation process.”
Allan Rewak, VP Communications and Stakeholder
Relations of Emerald, has been appointed as the Company’s formal
representative to ATACH and will utilize his experience in the
Canadian cannabis legalisation process to support the development
of a reasonable and effective regulatory regime for CBD in the
United States.
Emerald produces and sells its SYNC 25 CBD oil
in the adult-use market and other high-CBD products in the medical
market in Canada and has sourced hemp to produce allowable oils in
the current Canadian legal framework. It is also employing advanced
formulation and delivery technology with the goal to offer
customers new product choices in conjunction with new Canadian
legislation that is expected to allow a broader set of ingestible
and topical products in the fall of 2019 and beyond.
About the American Trade Association for
Cannabis & Hemp
The American Trade Association for Cannabis
& Hemp (“ATACH”) is a 501(c)(6) trade organization registered
in Washington, DC, founded to promote the expansion, protection,
and preservation of businesses engaged in the legal trade of
industrial, medical, and recreational cannabis and hemp-based
products.
ATACH is a place for marijuana and hemp industry
leaders and well known, well capitalized businesses who are
entering the industry to promote marketplace expansion, develop
regulation, and adopt industry standards.
ATACH is ushering in the next phase of
marketplace expansion by providing a bridge from the cannabis
industry to mainstream name brand businesses who will be partners
in advancing the industry and ending prohibition. The organization
is playing a leading role in professionalizing industry
representation and facilitating the next generation of the
marketplace.
About Emerald Health
Therapeutics
Emerald Health Therapeutics, Inc. is a Canadian
licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint
venture in BC is licensed and fully planted in the first of its two
1.1 million square foot greenhouses. The capacity of each
greenhouse is estimated to exceed 75,000 kg of cannabis annually.
Emerald’s Verdélite operation in Saint Eustache, Québec is
completing the build-out of its 88,000 square foot indoor
cultivation facility and is scaling up production. Emerald has
contracted for approximately 1000 acres of hemp in 2019 to 2022
with the objective of extracting low-cost cannabidiol. Emerald has
secured exclusive strategic partnerships for large scale extraction
and softgel encapsulation, as well as for proprietary technology to
enhance cannabinoid bioavailability. Its team is highly experienced
in life sciences, product development, large-scale agri-business,
and marketing, and is focused on developing proprietary,
value-added cannabis products for medical and adult-use
customers.
Emerald is part of the Emerald Health group,
which represents a broad array of companies focused on developing
pharmaceutical, botanical, and nutraceutical products aimed at
providing wellness and medical benefits by interacting with the
human body’s endocannabinoid system.
Please visit www.emeraldhealth.ca for more information or
contact: Rob Hill, Chief Financial Officer (800) 757 3536 Ext. #
5
Emerald Investor Relations (800) 757 3536 Ext.
#5invest@emeraldhealth.ca
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking
Statements: Certain statements made in this press release that are
not historical facts are forward-looking statements and are subject
to important risks, uncertainties and assumptions, both general and
specific, which give rise to the possibility that actual results or
events could differ materially from our expectations expressed in
or implied by such forward-looking statements. Such statements
include projected job creation figures at our operating facilities;
production and processing capacity of various facilities; expansion
of facilities; and anticipated production costs.
We cannot guarantee that any forward-looking
statement will materialize, and readers are cautioned not to place
undue reliance on these forward-looking statements. These
forward-looking statements involve risks and uncertainties related
to, among other things, failure to obtain regulatory approvals;
failure to obtain necessary financing; results of production and
sale activities; results of scientific research; regulatory
changes; changes in prices and costs of inputs; demand for labour;
demand for products; as well as the risk factors described in the
Company’s annual information form and other regulatory filings. The
forward-looking statements contained in this press release
represent our expectations as of the date hereof. Forward-looking
statements are presented for the purpose of providing information
about management's current expectations and plans and allowing
investors and others to obtain a better understanding of our
anticipated operating environment. Readers are cautioned that such
information may not be appropriate for other purposes. The Company
undertakes no obligations to update or revise such statements to
reflect new circumstances or unanticipated events as they occur,
unless required by applicable law.
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Feb 2024 to Mar 2024
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Mar 2023 to Mar 2024